These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 21643691

  • 1. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.
    Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C, Zamboni G.
    Virchows Arch; 2011 Jul; 459(1):1-10. PubMed ID: 21643691
    [Abstract] [Full Text] [Related]

  • 2. Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis.
    Sanpaolo P, Barbieri V, Pedicini P, Fusco V.
    Med Oncol; 2012 Jun; 29(2):459-65. PubMed ID: 21359639
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [Abstract] [Full Text] [Related]

  • 6. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
    Cancer; 2006 Aug 15; 107(4):696-704. PubMed ID: 16826579
    [Abstract] [Full Text] [Related]

  • 7. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.
    J BUON; 2012 Aug 15; 17(2):277-83. PubMed ID: 22740206
    [Abstract] [Full Text] [Related]

  • 8. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
    Breast Cancer Res; 2009 Aug 15; 11(1):R11. PubMed ID: 19239686
    [Abstract] [Full Text] [Related]

  • 9. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S, Staff S, Tanner M, Isola J.
    Tumour Biol; 2016 Jul 15; 37(7):9813-23. PubMed ID: 26810187
    [Abstract] [Full Text] [Related]

  • 10. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X, Fan Y, Xu B.
    Clin Breast Cancer; 2018 Dec 15; 18(6):e1353-e1360. PubMed ID: 30201586
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S, Fathallah K, Rouatbi R, Ayachi M, Hmissa S, Mokni M.
    Pathol Oncol Res; 2015 Jul 15; 21(3):553-61. PubMed ID: 25962349
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G, Beadle G, Thomas S, Mengersen K, Stein S.
    Pathology; 2006 Oct 15; 38(5):391-8. PubMed ID: 17008275
    [Abstract] [Full Text] [Related]

  • 14. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D, Xu S, Zhang Q, Zhao W.
    Med Oncol; 2012 Jun 15; 29(2):526-33. PubMed ID: 21519872
    [Abstract] [Full Text] [Related]

  • 15. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH, Shabahang H, Afzaljavan F, Sharifi N, Tavasoli A, Afzalaghaee M, Roshanzamir E, Pasdar A.
    Asian Pac J Cancer Prev; 2016 Jun 15; 17(3):1347-50. PubMed ID: 27039770
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
    Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.
    Med Oncol; 2009 Dec 15; 26(4):480-90. PubMed ID: 19130322
    [Abstract] [Full Text] [Related]

  • 18. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S, Himakhun W, Worasawate W, Prasert W.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1559-1565. PubMed ID: 32592349
    [Abstract] [Full Text] [Related]

  • 19. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.
    Asian Pac J Cancer Prev; 2015 Jun 01; 16(4):1643-9. PubMed ID: 25743846
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.